IP Library › Granted Patent US 10,421,717
Granted Patent B2
US 10,421,717 · App. 15/772,607 · Granted Sep 24, 2019

Process for preparing brivaracetam

Inventors: Thierry Defrance (Brussels, BE); Jean Septavaux (Marseilles, FR); Didier Nuel (Marseilles, FR)
Assignee: UCB Biopharma SPRL
C07D207/27C07D207/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,421,717
App. No.
15/772,607
Granted
Sep 24, 2019
Kind
B2
Abstract

The present invention relates to a new process for preparing brivaracetam. (Ib)

Claims (16)

1. A process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide (brivaracetam) in an enriched amount ranging from a 78.5/21.5 to 83/17 ratio in favor of the brivaracetam diastereomer, through catalytic reduction performed according to the following reaction:

whereby the Catalyst is either of the following:

Pt/C; with the addition of formic acid or citric acid;

Pd/C; with the addition of citric acid or formic acid;

Ir/CaCO 3 with the addition of formic acid or citric acid.

2. The process according to claim 1 , wherein the Catalyst is either of the following:

Pt/C; with the addition of formic acid;

Pd/C; with the addition of citric acid;

Ir/CaCO 3 with the addition of formic acid.

3. The process according to claim 1 , which is performed in a polar solvent or in a polar aprotic solvent or in an apolar solvent.

4. The process according to claim 3 , which is performed in water.

5. The process according to claim 1 , wherein the hydrogen pressure is usually adjusted at any value between 5-40 bars.

6. The process according to claim 1 , wherein Pt/C; with the addition of formic acid, in an amount of 2 eq is used as catalytic system (Catalyst).

7. The process according to claim 1 , wherein Pd/C; with the addition of citric acid, in an amount of 2 eq is used as catalytic system (Catalyst).

8. The process according to claim 1 , wherein Ir/CaCO 3 with the addition of formic acid, in an amount of 2 eq is used as catalytic system (Catalyst).

9. A process for the preparation of an essentially pure (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide (brivaracetam) having a ratio of at least 97/3, through catalytic reduction performed according to claim 1 followed by a MCC.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Jul 29, 2026
From: UCB BIOPHARMA SRL (FORMERLY KNOWN AS UCB BIOPHARMA SPRL)
To: UCB DEVELOPED BRANDS SRL
Reel/Frame 076077/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: DEFRANCE, THIERRY; SEPTAVAUX, JEAN; NUEL, DIDIER
To: UCB BIOPHARMA SPRL
Reel/Frame 045998/0329 →
Priority Claims (1)
EP 15192760 · Nov 3, 2015 · regional
Continuity (1)
Related Publication 20190119206A1 · Apr 25, 2019
Cited By (1)
US 12,247,071